The main effects and side effects of Ustekinumab injection

Ustekinumab (Ustekinumab) is a targeted therapy drug that belongs to the monoclonal antibody class and is mainly used to treat a variety of immune-mediated inflammatory diseases, such as psoriasis, psoriatic arthritis, and Crohn's disease. It reduces inflammation and related symptoms by inhibiting specific inflammatory pathways in the body's immune system. This article will introduce in detail the main effects and common side effects of ustekinumab injection to help patients and medical staff better understand the use and precautions of this drug.

1. The main effects of ustekinumab

Ustekinumab is a monoclonal antibody directed against the IL-12 and IL-23 cytokines. These two cytokines play an important regulatory role in the human immune system, especially in regulating inflammatory responses and immune cell activity. IL-12 and IL-23 are involved in the pathological processes of a variety of autoimmune diseases and can lead to inflammation and tissue damage when overactive.

Ustekinumab binds to and blocks the p40 subunits of IL-12 and IL-23, blocking their binding to receptors, thereby inhibiting downstream inflammatory signaling and reducing the release of inflammatory mediators. This mechanism helps reduce chronic inflammatory conditions in patients and improve disease symptoms.

1.Psoriasis (plaque psoriasis) treatment

In patients with psoriasis, ustekinumab is effective in reducing skin erythema, scaling, and itching. Clinical data shows that after injection treatment, the area of u200bu200bskin lesions in many patients is significantly reduced within a short period of time, and some patients even achieve complete remission. Ustekinumab is recommended as one of the first-choice biologics for moderate to severe plaque psoriasis.

2.Control of psoriatic arthritis

For psoriasis patients with arthritis, ustekinumab can not only improve skin symptoms, but also significantly relieve joint pain, swelling and limited mobility, reduce the risk of joint damage, and improve the patient's quality of life.

3.Crohn’s disease and other inflammatory bowel diseases

In patients with Crohn's disease, ustekinumab helps maintain long-term remission by reducing intestinal inflammation, improving symptoms such as abdominal pain, diarrhea, and weight loss, while promoting the healing of the intestinal mucosa.

In summary, ustekinumab, as an immunomodulator, can effectively inhibit the inflammatory response in a variety of immune-mediated diseases and improve patients' clinical manifestations and quality of life.

2. Common side effects after ustekinumab injection

Although ustekinumab is highly effective, as an immunosuppressive drug, certain side effects may still occur during use. Most common side effects are mild and can be alleviated by adjusting treatment or symptomatic management.

1.Injection site reaction

This is the most common side effect and includes pain, redness, swelling, itching, or hardness at the injection site. In most cases, these reactions resolve spontaneously within a few days and do not affect continued use of the medication.

2.Increased risk of infection

Because ustekinumab suppresses some functions of the immune system, patients may be at increased risk of upper respiratory tract infections, urinary tract infections, or other bacterial or viral infections. Patients should pay close attention to symptoms of infection during use and seek medical treatment promptly.

3.Headache and fatigue

Some patients may experience discomfort such as headache, fatigue or mild fever after injection. Such side effects are generally short-lived and gradually reduce as the treatment adapts.

4.Gastrointestinal reactions

Occasionally, patients report symptoms such as nausea, diarrhea, or indigestion, which may be related to the drug's modulation of immune status, but the overall incidence is low.

3. Serious side effects that are rare but require vigilance

As an immunomodulator, ustekinumab may cause serious but rare side effects, and patients and doctors need to remain vigilant.

1.Serious infection

For example, if pneumonia, tuberculosis or opportunistic infections occur, medication must be stopped immediately and active treatment must be received. Screening for infectious diseases such as tuberculosis is often required before treatment.

2.Allergic reaction

Although rare, some patients may experience severe allergic reactions, such as urticaria, difficulty breathing, facial swelling, etc., and should be treated urgently.

3.Tumor risk

Long-term use of immunosuppressants may slightly increase the risk of certain tumors, but the evidence is currently insufficient and needs to be combined with the patient's own risk assessment.

4.Nervous system response

A very small number of patients report symptoms of neuropathy, such as blurred vision, numbness, etc., which require prompt evaluation and investigation.

4. Medication precautions and suggestions

Before using ustekinumab, patients should undergo a comprehensive physical examination and medical history evaluation to rule out active infections and serious immune system diseases. During the treatment process, patients need to regularly review blood routine, liver and kidney function, and infection indicators.

When injecting, you should strictly follow the doctor's instructions and drug instructions, and avoid adjusting the dosage or frequency on your own. Care of the injection site can reduce local discomfort.

In addition, patients should inform their doctors of all medications they are taking to avoid excessive suppression of immune function due to combination with other immunosuppressants or biological agents.

Overall, ustekinumab plays an important role in effectively controlling inflammatory diseases, but side effects need to be properly monitored to ensure safe use. If patients find abnormal reactions, they should seek medical advice promptly and obtain professional guidance. Through scientific and standardized treatment, ustekinumab can significantly improve patients' quality of life and improve disease prognosis.

Reference materials:https://www.drugs.com/donanemab.html